MapLight Therapeutics (MPLT) Current Leases (2024 - 2025)
MapLight Therapeutics (MPLT) reported Current Leases of $891000.0 for Q4 2025, up 14.52% on a YoY basis from $778000.0 in Q4 2024, and up 3.36% sequentially from $862000.0 in Q3 2025.
MapLight Therapeutics (MPLT) Current Leases (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Current Leases data on file, last reported at $891000.0 in Q4 2025.
- For the quarter ending Q4 2025, Current Leases rose 14.52% year-over-year to $891000.0; the trailing twelve-month figure through Dec 2025 stood at $891000.0 (up 14.52% YoY), and the FY2025 full-year result was $891000.0, up 14.52% from the prior year.
- Current Leases advanced to $891000.0 in Q4 2025, from $862000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $891000.0 in Q4 2025 to a low of $778000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 531,233.95 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 20.58 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 872,589.03 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 720.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 11.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.61 Mn |
| 10 | MapLight Therapeutics | 305.82 Mn | 305.82 Mn | - | 891,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 891,000.00 |
| Sep 30, 2025 | 862,000.00 |
| Dec 31, 2024 | 778,000.00 |